Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD


Graft Versus Host Disease | Leukemia | Myelodysplastic Syndromes

What is the purpose of this trial?

RATIONALE: Allogeneic hematopoietic stem cell transplant (HSCT) is a treatment that can cure
acute leukemia and myelodysplasia. After giving the patient chemotherapy and total body
irradiation to stop the growth of cancer and remove the patient's diseased bone marrow,
healthy stem cells from a donor are infused into the patient to replace the patient's bone
marrow and make red and white blood cells and platelets. Unfortunately HSCT is often
complicated by 'graft versus host disease' (GVHD) in which the transplanted cells from a
donor can make an immune response against the body's normal cells and cause tissue damage
and severe symptoms. Removing a subset of the donor T cells, called 'naive T cells', before
transplant may reduce the frequency and intensity of GVHD.

PURPOSE: This phase II trial will determine whether the removal of the naive T cells from
donor cells can decrease the rate and severity of graft-vs-host disease while preserving
specific immunity against infections in patients with acute leukemia or advanced
myelodysplastic syndromes.

Participation Guidelines

14 Years - 55 Years

Click here for detailed information about who can participate in this trial.

Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Yale University
October 2009
Last Updated:
June 12, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00914940